Pharmaceuticals
Biocon arm gets USFDA nod for generic Everolimus tablets
Biocon's arm, Biocon Pharma Ltd, has secured USFDA approval for its generic Everolimus tablets. This medication aids in treating tuberous sclerosis complex, a rare genetic disorder causing tumors. The approval for 2mg, 3mg, and 5mg strengths bolsters Biocon's drug offerings, providing a new treatment option for adult and pediatric patients with specific TSC-related conditions.
Alembic Pharmaceuticals gets USFDA tentative nod for generic cancer treatment drug
Alembic Pharmaceuticals has secured tentative approval from the USFDA for its Bosutinib tablets. These tablets are used to treat certain types of cancer, specifically chronic myelogenous leukemia. The approval covers the 400 mg strength. This development marks a significant step for Alembic in the US market. The company previously received final approval for other strengths of the same drug.
Delhi HC clears Zydus to sell biosimilar of BMS cancer drug Nivolumab
The Delhi High Court has permitted Zydus Lifesciences to produce and market a biosimilar cancer drug. This decision comes as the patent for the original drug, Nivolumab, nears its expiration. The court prioritized patient access to affordable treatment. Zydus can now proceed with its biosimilar, ZRC-3276, while maintaining sales records.
Budget 2026: Pharma, med-tech companies seek PLI extension to cover APIs
The industry expects the government to address these issues in the Union budget announcement this year. Sudarshan Jain, secretary general of Indian Pharmaceutical Alliance (IPA) said the recent global challenges like US tariffs, supply chain disruptions and geopolitical uncertainty have underscored the need for strategic support, and hence, restoring 200% weighted deduction for research and development expenditures would be a significant step.
Aurobindo Pharma’s Dyrupeg faces Health Canada compliance notice
CuraTeQ Biologics, a part of Aurobindo Pharma, has secured a crucial approval from Health Canada for its biosimilar drug Dyrupeg. This medication helps cancer patients with low neutrophil counts. The approval confirms Dyrupeg's high similarity to an existing reference biologic drug. Earlier, Dyrupeg also gained marketing authorization in the European Union and the UK.
Canadian pharmacy platform to offer India-sourced Ozempic to US patients
SaveRxCanada.to, an online pharmacy platform, announced it is now offering Ozempic sourced from India to U.S. patients at significantly lower prices than U.S. retail pharmacies. The company claims to connect patients with licensed international pharmacies, though Novo Nordisk denies any relationship with the platform.
Cardiac drugs log highest sales in 2025 as NCD cases surge
Heart medicines led sales in 2025, a trend set to continue. Respiratory and anti-diabetes drugs followed. Cardiac drug sales grew 13%, with similar strong performance expected. Rising non-communicable diseases like hypertension fuel this growth. Increased awareness and longer treatment durations contribute.
Alkem Laboratories introduces hair growth support therapy kit
Alkem Laboratories has launched a new therapy kit to support hair growth. The Renocia cyclical therapy kit offers a weekly nutritional supplementation regimen. It aims to strengthen hair follicles and manage hair loss. The supplements are made using only vegetarian-sourced ingredients. This structured approach ensures better nutrient absorption.
Sun Pharma Advanced Research to cut workforce by 40%
Sun Pharma Advanced Research is significantly cutting its workforce. The company plans to reduce overall headcount by 40%. More than 80% of its US staff will also be let go. These moves aim to optimize costs and boost future growth. The company is also finalizing resourcing plans for upcoming financial years.
Granules India gets USFDA tentative nod for generic ADHD treatment tablets
Granules Pharmaceuticals, Inc., a subsidiary of Granules India, has achieved a significant milestone with the tentative green light from US health authorities for its generic amphetamine extended-release tablets, designed for managing attention deficit hyperactivity disorder.
Must Watch
Future diabetes care seen leaning towards GLP-1 drugs
The diabetes treatment landscape in India is on the brink of transformation. Innovative GLP-1 medications are set to redefine therapy standards, providing remarkable advantages in glucose regulation and weight management, while also safeguarding vital organs such as the heart and kidneys.
Budget 2026: Volume to value - How India can get a quiet superpower
India Budget: India's pharmaceutical industry, a global leader in volume, is poised to leverage its scale for greater international influence. The upcoming Union Budget 2026-27 presents a crucial opportunity to shift focus from low-margin generics to high-value segments like biologics and novel drug discovery.
Budget for 'pharmacy of the world': What Sitharaman & Co can do to make medicines more affordable in India
Union Budget 2026: India's pharmaceutical landscape is on the brink of a transformative boom. To maintain this upward trajectory, the focus must shift towards fostering innovation and enhancing the efficiency of drug manufacturing. Strategic government funding is essential to bolster research initiatives, support production facilities, and strengthen healthcare frameworks.
Ministry in talks with states to give some drug cos more time for good manufacturing practices compliance
The Union Health Ministry is in talks with states about extending the deadline for pharmaceutical companies to meet new manufacturing quality rules. A six-month extension may be granted on a case-by-case basis. This move aims to prevent potential medicine shortages and job losses. Many smaller drug units might otherwise face closure.
Doctors warn against antibiotic misuse as resistance threat grows
Leading doctors are warning the public about the dangers of antibiotic resistance. They stress that antibiotics must only be used under a doctor's prescription. Careless use is making infections harder to treat. India is a major consumer of these medicines. Many hospital infections now resist common antibiotics. This misuse threatens future healthcare. Patients, doctors, and the industry must act responsibly.
Obesity treatment drugs to be new growth engine for pharma industry: Sun Pharma
India, known for its generic drug industry, is rapidly transforming into a major hub for global weight management industry, amid rapid increase in obesity-led disease burden.
